Literature DB >> 9391118

Gene transfer of Fas ligand induces tumor regression in vivo.

H Arai1, D Gordon, E G Nabel, G J Nabel.   

Abstract

The Fas-Fas ligand (FasL) system plays an important role in the induction of lymphoid apoptosis and has been implicated in the suppression of immune responses. Herein, we report that gene transfer of FasL inhibits tumor cell growth in vivo. Although such inhibition is expected in Fas+ tumor cell lines, marked regression was unexpectedly observed after FasL gene transfer into the CT26 colon carcinoma that does not express Fas. Infection by an adenoviral vector encoding FasL rapidly eliminated tumor masses in the Fas+ Renca tumor by inducing cell death, whereas the elimination of Fas- CT26 cells was mediated by inflammatory cells. Analysis of human malignancies revealed Fas, but not FasL, expression in a majority of tumors and susceptibility to FasL in most Fas+ cell lines. These findings suggest that gene transfer of FasL generates apoptotic responses and induces potent inflammatory reactions that can be used to induce the regression of malignancies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9391118      PMCID: PMC28398          DOI: 10.1073/pnas.94.25.13862

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Fas ligation triggers apoptosis in macrophages but not endothelial cells.

Authors:  B C Richardson; N D Lalwani; K J Johnson; R M Marks
Journal:  Eur J Immunol       Date:  1994-11       Impact factor: 5.532

2.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

3.  Ly-6C is a monocyte/macrophage and endothelial cell differentiation antigen regulated by interferon-gamma.

Authors:  M A Jutila; F G Kroese; K L Jutila; A M Stall; S Fiering; L A Herzenberg; E L Berg; E C Butcher
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

4.  The beige mutation in the mouse selectively impairs natural killer cell function.

Authors:  J Roder; A Duwe
Journal:  Nature       Date:  1979-03-29       Impact factor: 49.962

Review 5.  The nude mouse in cancer research.

Authors:  B C Giovanella; J Fogh
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

6.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.

Authors:  N Itoh; S Yonehara; A Ishii; M Yonehara; S Mizushima; M Sameshima; A Hase; Y Seto; S Nagata
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

7.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

Authors:  E R Fearon; D M Pardoll; T Itaya; P Golumbek; H I Levitsky; J W Simons; H Karasuyama; B Vogelstein; P Frost
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

8.  Lethal effect of the anti-Fas antibody in mice.

Authors:  J Ogasawara; R Watanabe-Fukunaga; M Adachi; A Matsuzawa; T Kasugai; Y Kitamura; N Itoh; T Suda; S Nagata
Journal:  Nature       Date:  1993-08-26       Impact factor: 49.962

9.  Gene therapy for vascular smooth muscle cell proliferation after arterial injury.

Authors:  T Ohno; D Gordon; H San; V J Pompili; M J Imperiale; G J Nabel; E G Nabel
Journal:  Science       Date:  1994-08-05       Impact factor: 47.728

10.  The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo.

Authors:  Z Y Yang; N D Perkins; T Ohno; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

View more
  57 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death.

Authors:  N V Somia; M J Schmitt; D E Vetter; D Van Antwerp; S F Heinemann; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 3.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

4.  Transcription-controlled gene therapy against tumor angiogenesis.

Authors:  Shoshana Greenberger; Aviv Shaish; Nira Varda-Bloom; Keren Levanon; Eyal Breitbart; Iris Goldberg; Iris Barshack; Israel Hodish; Niva Yaacov; Livnat Bangio; Tanya Goncharov; David Wallach; Dror Harats
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

5.  Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Authors:  Jaime F Modiano; Beth A Lindborg; Ron T McElmurry; Mitzi Lewellen; Colleen L Forster; Edward A Zamora; Jerome Schaack; Donald Bellgrau; Timothy D O'Brien; Jakub Tolar
Journal:  Cancer Immunol Immunother       Date:  2015-08-07       Impact factor: 6.968

Review 6.  Fas (CD95, Apo-1) ligand gene transfer.

Authors:  S E Lamhamedi-Cherradi; Y Chen
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

7.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

Review 8.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

Review 9.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

10.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Authors:  Céline A Blache; Edwin R Manuel; Teodora I Kaltcheva; Andrea N Wong; Joshua D I Ellenhorn; Bruce R Blazar; Don J Diamond
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.